You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》瑞信升復星醫藥(02196.HK)評級至「中性」 目標價上調至33.18元
阿思達克 08-27 10:44
瑞信發表報告指,復星醫藥(02196.HK)今年第二季收入按年增長10.8%至81.48億元人民幣,純利按年增長41.5%至11.38億元。上半年收入及純利分別佔該行今年全年預測的44.9%及50.8%。

該行表示,復星醫藥與BioNTech及輝瑞正在中國研發新型肺炎疫苗,假設成功率為25%,預期集團今年在新型肺炎產生的銷售為12.33億元人民幣。由於生產產能增加,明年及2022年有關銷售估計可增加至各28.13億元人民幣。

瑞信上調復星醫藥股份評級,由「跑輸大市」升至「中性」,目標價由24.5元上調至33.18元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account